$79.33
2.553.32%
Ult. Agg.: Oct 26, 4:00 PM
Dianthus Therapeutics (DNTH) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.91 | $-1.12 | $-1.01 | $-0.88 |
| Actual | $-0.90 | $-0.85 | $-1.43 | $-0.97 |
| Surprise | +1.10% | +24.1% | -41.6% | -10.2% |
| Revenue | ||||
| Estimate | $293000 | $396952 | $476950 | $578184 |
| Actual | $761000 | $463000 | $284000 | $396000 |
| Surprise | +159.7% | +16.6% | -40.5% | -31.5% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.96 | $-1.10 | $-1.08 | $-1.14 |
| Revenue | ||||
| Consensus | $433136 | $344952 | — | — |
| Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
|---|---|---|---|---|
| Q2 | Aug 4, 2026 | $-0.90 | $-0.91 | 1.10 % |
| Q1 | May 5, 2026 | $-0.85 | $-1.12 | 24.1 % |
| Q4 | Mar 9, 2026 | $-1.43 | $-1.01 | -41.6 % |
| Q3 | Nov 5, 2025 | $-0.97 | $-0.88 | -10.2 % |
| Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
|---|---|---|---|---|
| Q2 | Aug 4, 2026 | $761.00K | $293.00K | 159.7 % |
| Q1 | May 5, 2026 | $463.00K | $396.95K | 16.6 % |
| Q4 | Mar 9, 2026 | $284.00K | $476.95K | -40.5 % |
| Q3 | Nov 5, 2025 | $396.00K | $578.18K | -31.5 % |